Phase I first-in-human clinical study of S-trans, trans- farnesylthiosalicylic acid (salirasib) in patients with solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 2, 2010, Pages 235-241

  Tsimberidou, Apostolia Maria ^a   Rudek, Michelle A ^b   Hong, David ^a   Ng, Chaan S ^a   Blair, Jessica ^a   Goldsweig, Howard ^c   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c Averion International Corp   (United States)

Author keywords

FTS; Pharmacokinetics; Phase I; Solid tumors; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; DIPHENOXYLATE; FARNESYLTHIOSALICYLIC ACID; LOPERAMIDE; SALIRASIB; UNCLASSIFIED DRUG; DRUG DERIVATIVE; FARNESOL; SALICYLIC ACID DERIVATIVE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; FATIGUE; HUMAN; LYMPHOMA; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; VOMITING; CHEMISTRY; FEMALE; MALE; MIDDLE AGED; NEOPLASM; STEREOISOMERISM;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FARNESOL; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; SALICYLIC ACIDS; STEREOISOMERISM;

EID: 71349085359     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1027-4     Document Type: Article

References (28)

1. Y Kloog AD Cox M Sinensky 1999 Concepts in Ras-directed therapy Expert Opin Investig Drugs 8 12 2121 2140 10.1517/13543784.8.12.2121 1:CAS:528:DyaK1MXns1eisLk%3D 11139843 (December)
2. DR Lowy BM Willumsen 1993 Function and regulation of ras Annu Rev Biochem 62 851 891 10.1146/annurev.bi.62.070193.004223 1:CAS:528:DyaK3sXlsFCjuro%3D 8352603
3. JM Shields K Pruitt A McFall A Shaub CJ Der 2000 Understanding Ras: 'it ain't over 'til it's over' Trends Cell Biol 10 4 147 154 10.1016/S0962-8924(00) 01740-2 1:CAS:528:DC%2BD3cXit1Sqtr0%3D 10740269 (April) (Pubitemid 30171309)
4. J Downward 2003 Targeting RAS signalling pathways in cancer therapy Nat Rev Cancer 3 1 11 22 10.1038/nrc969 1:CAS:528:DC%2BD38XpvVertbo%3D 12509763 (January) (Pubitemid 37328883)
5. JL Bos 1989 Ras oncogenes in human cancer: a review Cancer Res 49 17 4682 4689 1:CAS:528:DyaL1MXltlWksL4%3D 2547513 (1 September)
6. D Marciano G Ben-Baruch M Marom Y Egozi R Haklai Y Kloog 1995 Farnesyl derivatives of rigid carboxylic acids-inhibitors of ras-dependent cell growth J Med Chem 38 8 1267 1272 10.1021/jm00008a004 1:CAS:528:DyaK2MXkvVWruro%3D 7731012 (14 April)
7. G Elad A Paz R Haklai D Marciano A Cox Y Kloog 1999 Targeting of K-Ras 4B by S-trans, trans-farnesyl thiosalicylic acid Biochim Biophys Acta 1452 3 228 242 10.1016/S0167-4889(99)00144-5 1:CAS:528:DyaK1MXnslyltrc%3D 10590312 (9 December)
8. B Jansen E Heere-Ress H Schlagbauer-Wadl, et al. 1999 Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice J Mol Med 77 11 792 797 10.1007/s001099900052 1:CAS:528: DC%2BD3cXmsFSlsw%3D%3D 10619439 (November)
9. DB Whyte P Kirschmeier TN Hockenberry, et al. 1997 K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors J Biol Chem 272 22 14459 14464 10.1074/jbc.272.22.14459 1:CAS:528: DyaK2sXjsFygs74%3D 9162087 (30 May) (Pubitemid 27232866)
10. FL Zhang P Kirschmeier D Carr, et al. 1997 Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I J Biol Chem 272 15 10232 10239 10.1074/jbc.272.15.10232 1:CAS:528:DyaK2sXisFOmurg%3D 9092572 (11 April) (Pubitemid 27171703)
11. GL James JL Goldstein MS Brown, et al. 1993 Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells Science 260 5116 1937 1942 10.1126/science.8316834 1:CAS:528:DyaK3sXltlWjtLg%3D 8316834 (25 June)
12. NE Kohl SD Mosser SJ deSolms, et al. 1993 Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor Science 260 5116 1934 1937 10.1126/science.8316833 1:CAS:528:DyaK3sXltlWjtLs%3D 8316833 (25 June)
13. R Haklai G Elad-Sfadia Y Egozi Y Kloog 2008 Orally administered FTS (salirasib) inhibits human pancreatic tumor growth in nude mice Cancer Chemother Pharmacol 61 1 89 96 10.1007/s00280-007-0451-6 1:CAS:528:DC%2BD2sXhtFSrtbfN 17909812 (January) (Pubitemid 47512630)
14. R Blum R Elkon S Yaari, et al. 2007 Gene expression signature of human cancer cell lines treated with the ras inhibitor salirasib (S- farnesylthiosalicylic acid) Cancer Res 67 7 3320 3328 10.1158/0008-5472.CAN-06- 4287 1:CAS:528:DC%2BD2sXksVGks7c%3D 17409441 (1 April) (Pubitemid 46724871)
15. R Blum J Jacob-Hirsch G Rechavi Y Kloog 2006 Suppression of survivin expression in glioblastoma cells by the Ras inhibitor farnesylthiosalicylic acid promotes caspase-dependent apoptosis Mol Cancer Ther 5 9 2337 2347 10.1158/1535-7163.MCT-06-0193 1:CAS:528:DC%2BD28Xps1ynsb4%3D 16985068 (September) (Pubitemid 44530471)
16. B Jansen H Schlagbauer-Wadl H Kahr, et al. 1999 Novel Ras antagonist blocks human melanoma growth Proc Natl Acad Sci USA 96 24 14019 14024 10.1073/pnas.96.24.14019 1:CAS:528:DyaK1MXns1Oqu7w%3D 10570191 (23 November)
17. M Gana-Weisz J Halaschek-Wiener B Jansen G Elad R Haklai Y Kloog 2002 The Ras inhibitor S-trans, trans-farnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance Clin Cancer Res 8 2 555 565 1:CAS:528:DC%2BD38XitFensrs%3D 11839677 (February)
18. P Therasse SG Arbuck EA Eisenhauer, et al. 2000 New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 3 205 216 10.1093/jnci/92.3.205 1:STN:280:DC%2BD3c7it1Gitg%3D%3D 10655437 (2 February)
19. Concordia Pharmaceuticals, Inc., Ft. Lauderdale, FL, Company report
20. VP Shah KK Midha S Dighe, et al. 1991 Analytical methods validation: bioavailability, bioequivalence and pharmacokinetic studies. Conference report Eur J Drug Metab Pharmacokinet 16 4 249 255 1:STN:280:DyaK38zoslWktA%3D%3D 1823867 (October-December)
21. Gibaldi M, Perrier D (1982) Noncompartmental analysis based on statistical moment theory Pharmacokinetics. Marcel Dekker, New York, pp 409-417
22. Y Hirokawa A Tikoo J Huynh, et al. 2004 A clue to the therapy of neurofibromatosis type 2: NF2/merlin is a PAK1 inhibitor Cancer J 10 1 20 26 10.1097/00130404-200401000-00006 1:CAS:528:DC%2BD2cXnvFWkurc%3D 15000491 (January-February)
23. JR Jung H Kim SS Jeun JY Lee EJ Koh C Ji 2005 The Phosphorylation status of merlin is important for regulating the Ras-ERK pathway Mol Cells 20 2 196 200 1:CAS:528:DC%2BD2MXht1KqsL7I 16267393 (31 October)
24. H Morrison T Sperka J Manent M Giovannini H Ponta P Herrlich 2007 Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac Cancer Res 67 2 520 527 10.1158/0008-5472.CAN-06-1608 1:CAS:528:DC%2BD2sXmtVKltw%3D%3D 17234759 (15 January) (Pubitemid 46192188)
25. KH Yohay 2006 The genetic and molecular pathogenesis of NF1 and NF2 Semin Pediatr Neurol 13 1 21 26 10.1016/j.spen.2006.01.007 16818172 (March) (Pubitemid 43963397)
26. W Yue J Wang Y Li P Fan RJ Santen 2005 Farnesylthiosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells Int J Cancer 117 5 746 754 10.1002/ijc.21222 1:CAS:528:DC%2BD2MXht1ShsbbN 15957161 (10 December) (Pubitemid 41598825)
27. RJ Santen AR Lynch LR Neal RA McPherson W Yue 2006 Farnesylthiosalicylic acid: inhibition of proliferation and enhancement of apoptosis of hormone-dependent breast cancer cells Anticancer Drugs 17 1 33 40 10.1097/01.cad.0000185184.64980.39 1:CAS:528:DC%2BD2MXht1Glt7%2FK 16317288 (January)
28. A Khwaja CC Sharpe M Noor Y Kloog BM Hendry 2005 The inhibition of human mesangial cell proliferation by S-trans, trans-farnesylthiosalicylic acid Kidney Int 68 2 474 486 10.1111/j.1523-1755.2005.00425.x 1:CAS:528: DC%2BD2MXpt1Wmsrc%3D 16014024 (August) (Pubitemid 43323102)